IL-1ra administration does not improve cardiac function in patients with severe sepsis

J Crit Care. 1999 Jun;14(2):69-72. doi: 10.1016/s0883-9441(99)90016-3.

Abstract

Purpose: The purpose of this study was to investigate the effects of interleukin-1 receptor antagonist (IL-1ra) on myocardial function in septic patients.

Materials and methods: A subgroup of patients from a prospective, randomized, double-blind, placebo-controlled, multicenter trial was studied from 63 academic medical centers in the United States, Canada, and Europe. A subgroup of 71 patients with severe sepsis in whom vasoactive support was little altered during the study was included. The patients were randomized to receive either placebo (n = 29) or IL-1ra at a dose of 1 mg/kg/h (n = 20) or 2 mg/kg/h (n = 22).

Results: Hemodynamic measurements were taken at baseline, and 1, 2, 3, 4, 8, and 12 hours after placebo or IL-1ra administration. No significant differences in hemodynamic parameters were observed between the groups or over time during the study period.

Conclusions: IL-1ra administration has no effect on cardiac function in septic patients.

Publication types

  • Clinical Trial
  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Blood Gas Analysis
  • Critical Illness
  • Double-Blind Method
  • Drug Monitoring
  • Hemodynamics / drug effects*
  • Humans
  • Infusions, Intravenous
  • Interleukin 1 Receptor Antagonist Protein
  • Myocardial Contraction / drug effects*
  • Prospective Studies
  • Sepsis / blood
  • Sepsis / drug therapy*
  • Sepsis / immunology
  • Sepsis / physiopathology*
  • Sialoglycoproteins / immunology
  • Sialoglycoproteins / pharmacology
  • Sialoglycoproteins / therapeutic use*

Substances

  • IL1RN protein, human
  • Interleukin 1 Receptor Antagonist Protein
  • Sialoglycoproteins